Get started
Author

Andreas Jakob

Thymic Carcinoma with Overexpression of MutatedKITand the Response to Imatinib
2004 · Philipp Ströbel, Martina Hartmann, et al. · New England Journal of Medicine · 182
PDF
Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients
2007 · C Heining, A Spyridonidis, et al. · Bone Marrow Transplantation · 71
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
2005 · J. T. Hartmann, K. Oechsle, et al. · Investigational New Drugs · 54
Severe cold hemagglutinin disease (CHD) successfully treated with rituximab
2002 · Monika Engelhardt, Andreas Jakob, et al. · Blood · 35
PDF
Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study
2022 · Andreas Jakob, Mark-Oliver Zahn, et al. · Journal of bone oncology · 16
PDF
Limitations of N-Terminal Pro-B-Type Natriuretic Peptide in the Diagnosis of Heart Disease among Cancer Patients Who Present with Cardiac or Pulmonary Symptoms
2016 · Siegfried Wieshammer, Jens Dreyhaupt, et al. · Oncology · 16
Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study
2013 · Lothar Bergmann, Peter J. Goebell, et al. · Oncology Research and Treatment · 15
Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation—a phase II study
2002 · A Jakob, C Bokemeyer, et al. · Anti-Cancer Drugs · 14
The Effect of Collaborative Reviews of Electronic Patient-Reported Outcomes on the Congruence of Patient- and Clinician-Reported Toxicity in Cancer Patients Receiving Systemic Therapy: Prospective, Multicenter, Observational Clinical Trial
2021 · Andreas Trojan, Nicolas Leuthold, et al. · Journal of Medical Internet Research · 13
PDF
186Rhenium-labeled anti-CD20 antibody radioimmunotherapy followed by autologous peripheral blood stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma
2004 · Stefan Knop, Andreas Jakob, et al. · Blood · 11
PDF
Cardiotoxicity and Cancer Therapy: Treatment-Related Cardiac Morbidity in Patients Presenting with Symptoms Suggestive of Heart or Lung Disease
2013 · Siegfried Wieshammer, Jens Dreyhaupt, et al. · Oncology · 10
PDF
Effect of adjuvant bisphosphonates on disease-free survival in early breast cancer: Retrospective analysis results in an unselected single-center cohort
2013 · Peyman Hadji, Matthias Frank, et al. · Journal of bone oncology · 8
Successful treatment of a patient with myelodysplastic syndrome (RAEB) with Darbepoetin-alfa in combination with Pegfilgrastim
2005 · Andreas Jakob, Friedrich W. Hirsch, et al. · Annals of Hematology · 7
Venous thromboembolism and persistent pulmonary hypertension in cancer patients: a cross-sectional study
2016 · Siegfried Wieshammer, Jens Dreyhaupt, et al. · Thrombosis Journal · 6
PDF
A noninterventional study of everolimus in metastatic renal cell cancer after use of one VEGFR-TKI: Results of a preplanned interim analysis of a prospective study.
2011 · L. Bergmann, U. Kube, et al. · Journal of Clinical Oncology · 4
Unsupervised Dynamic Electronic Patient-Reported Outcome Reporting of Immunotherapy-Related Symptoms in Cancer Patients
2025 · Anna Kristina Stauffacher, Louise von Stockar, et al. · Oncology · 3
24-week home-based walking program in the early adjuvant setting in breast cancer patients who receive aromatase inhibitor endocrine therapy: lessons learned from the SAKK 95/17 WISE prospective, randomized, multicenter trial
2026 · Uwe Güth, Nicolette Hoefnagels, et al. · The Breast · 2
Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study
2024 · Michael Mark, Alfonso Rojas Mora, et al. · Bone Reports · 2
Abstract P4-14-04: AVANTI: A non-interventional study examining the combination of bevacizumab with paclitaxel or capecitabine in metastatic breast cancer
2013 · A Schneeweiss, W Fett, et al. · Cancer Research · 2
Retrospective Analysis of CD38 Expression in 102 Patients with B-CLL with a Maximum Follow-Up of 18 Years: Incidence and Prognostic Significance
2006 · Andreas Jakob, Jasmin Doll, et al. · Oncology Research and Treatment · 2
2167P Are bone targeted agents (BTAs) still useful in times of immunotherapy? The SAKK 80/19 BTA study
2023 · M.T. Mark, A. Rojas Mora, et al. · Annals of Oncology · 1
PDF
Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status: The SAKK 80/19 SMOKER study.
2023 · Tämer El Saadany, Ulf Petrausch, et al. · Journal of Clinical Oncology · 1
PDF
Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry
2016 · Uwe Platzbecker, Eva Lengfelder, et al. · Blood · 1
Abstract P4-13-26: Efficacy, safety, and treatment decision-making in the AVANTI German observational study of first-line bevacizumab (BEV)-containing therapy for locally advanced, recurrent, or metastatic breast cancer (aBC)
2016 · V Müller, A Jakob, et al. · Cancer Research · 1
Updated results of a prospective noninterventional study of everolimus after use of 1 VEGFR-TKI.
2012 · Lothar Bergmann, Peter J. Goebell, et al. · Journal of Clinical Oncology · 1
Works count: 50
Citation count: 479
H-index: 10
I10-index: 11
Year
Topic
Type